Methods of use of probiotic bifidobacteria for human beauty benefits

• US 8,926,952 B2
• Filed: 04/06/2006
• Issued: 01/06/2015
• Est. Priority Date: 04/08/2005
• Status: Active Grant

• Current Assignee: Alimentary Health Limited, The Procter & Gamble Company
• Original Assignee: Alimentary Health Limited, The Procter & Gamble Company
• Inventors: Trejo, Amy Violet, O'Mahony, Liam Diarmuid
• Primary Examiner(s): Ware, Debbie K
• Application Number:
  US11/398,943
• Publication Number:
  US 20070031393A1
• Time in Patent Office: 3,197 Days
• Field of Search: None
• US Class Current: 424/70.1
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A61K 2800/92 Oral administration
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 8/99 from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin
• CPC Class Codes: Y10S 435/822 using bacteria or actinomycetales

Abstract

Methods of use in humans of probiotic bacteria of the genus Bifidobacteria for regulating the condition of human keratinous tissue to achieve cosmetic beauty benefits. Said methods include regulation, either prophylactic or therapeutic, of the cosmetic appearance of human keratinous tissue, such as human hair, skin (e.g., scalp), and nails. In another aspect, the invention provides a method of marketing a composition comprising probiotic Bifidobacteria. In one embodiment, the method comprises: (1) offering for sale a composition comprising probiotic Bifidobacteria; and (2) communicating to a potential consumer of said composition that oral administration of said composition can regulate the condition of human keratinous tissue.

Claims

1. A method of regulating the condition of human keratinous tissue, comprising orally administering a probiotic strain of Bifidobacteria to a human seeking said regulation.

2. The method of claim 1, wherein said Bifidobacteria is isolated from the human gastrointestinal tract.

3. The method of claim 1, wherein said Bifidobacteria is selected from the group consisting of Bifidobacteria having accession numbers NCIMB 41050, NCIMB 41051, NCIMB 41052, NCIMB 41053, NCIMB 41099, NCIMB 41100, NCIMB 41003, mutants thereof, and mixtures thereof.

4. The method of claim 1, wherein said human keratinous tissue is human skin.

5. The method of claim 1, wherein said human keratinous tissue is human scalp.

6. The method of claim 1, wherein said human keratinous tissue is human nails.

7. The method of claim 1, wherein said human keratinous tissue is human hair.

8. A method of regulating the condition of human keratinous tissue, consisting of orally administering a probiotic strain of Bifidobacteria to a human seeking said regulation.

9. A method of regulating the condition of human keratinous tissue, comprising orally administering a probiotic strain of Bifidobacteria to a human seeking said regulation at a dose of at least about 2 grams per day.

10. A method of regulating the condition of human keratinous tissue, comprising orally administering a probiotic strain of Bifidobacteria to a human seeking said regulation, wherein the probiotic strain of Bifidobacteria is contained in a unit dose form within a sachet.